Related Experiment Video
Updated: Sep 29, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
685
CASC7: a LncRNA with potential clinical application
1The First Affiliated Hospital, Department of Gastroenterology, Hengyang Medical School, University of South China, Hengyang, China.
International Journal of Radiation Biology
|March 21, 2022
Summary
Cancer Susceptibility Candidate 7 (CASC7) is a novel long non-coding RNA (lncRNA) with abnormal expression in various cancers. Further research into CASC7 mechanisms and clinical significance is crucial for potential therapeutic applications.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Long non-coding RNAs (lncRNAs) are key regulators of biological processes.
- Cancer Susceptibility Candidate 7 (CASC7) is a novel lncRNA with nuclear and cytoplasmic localization.
- CASC7 expression is altered in various human cancers and other diseases.
Purpose of the Study:
- To review the current understanding of the novel lncRNA CASC7.
- To explore the molecular mechanisms underlying CASC7's function.
- To assess the clinical significance and potential applications of CASC7 in cancer.
Main Methods:
- Literature review of existing studies on CASC7.
- Analysis of publicly available databases for CASC7 expression patterns.
- Examination of CASC7's role in various cancers and other clinical conditions.
Main Results:
- CASC7 is differentially expressed in tumor tissues compared to normal organs.
- Aberrant CASC7 expression is observed in colorectal cancer, glioma, breast cancer, non-small cell lung cancer, and thyroid cancer.
- CASC7 may serve as a potential biomarker and therapeutic target for various diseases.
Conclusions:
- CASC7 is a novel lncRNA with limited existing research.
- Abnormal CASC7 expression is linked to the development and treatment of malignancies.
- Further investigation into CASC7's mechanisms and clinical utility is warranted.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
01:07MAPK Signaling Cascades
6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
01:22MicroRNAs
3.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K